Osi Pharmaceuticals Inc. (OSIP) downgraded to Sector Perform with price target $57.50 by RBC Capital Mkts
RBC Capital Mkts rated Sector Perform Osi Pharmaceuticals Inc. (NASDAQ: OSIP) on 05/17/2010. Previously RBC Capital Mkts rated Outperform Osi Pharmaceuticals Inc. (NASDAQ:
OSIP) on 07/13/2009., when the stock price was $30.36. Since then, Osi Pharmaceuticals Inc. has gained 89.03% as of 05/17/2010's recent price of $57.39. If you would have followed the previous RBC Capital Mkts's recommendation on OSIP, you would have gained 89.03% of your investment in 308 days.
OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship product is Tarceva (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom subsidiary. Roche Holding Ltd. and OSI announced that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC), which is aggravated following chemotherapy. In December 2008, the Company acquired from 7TM Pharma A/S, a number of early stage research assets and a G-Protein coupled receptor (GPCR), technology platform.
RBC Capital Markets is an international corporate and investment bank that provides innovative solutions and a focused set of products and services to institutions, corporations, governments and high net worth clients around the world. With nearly 3,700 professional and support staff, we operate out of 75 offices in 15 countries and deliver our products and services through operations in Asia and Australasia, the UK and Europe and in every major North American city.